A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)
The goal of this clinical research study is to learn if KTE-C19 can help to control relapsed/refractory MCL when given after a 3-day course of chemotherapy. The safety of the drug will also be studied.
Disease Group: Lymphoma
Treatment Agent: KTE-C19
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Kite Pharma, Inc.
IRB Review and Approval Date: 12/18/2015
Recruitment Status: Open
Projected Accrual: 80
Information and next steps
For general questions about clinical trials: